ArticleAIDS patient care and STDs2026
Early Implementation of Doxycycline Postexposure Prophylaxis at an Infectious Diseases Clinic in the Southern United States.
Article in AIDS patient care and STDs, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Doxycycline postexposure prophylaxis (DoxyPEP) is an emerging strategy to prevent bacterial sexually transmitted infections (STIs) among men who have sex with men (MSM) and transgender women (TGW). We evaluated early DoxyPEP implementation in a university-affiliated infectious diseases clinic providing HIV and pre-exposure prophylaxis (PrEP) care in Durham, North Carolina. This retrospective study included two overlapping cohorts: (1) patients prescribed DoxyPEP through December 31, 2024, to characterize early prescribing and follow-up with contextual clinic comparison; and (2) MSM and TGW diagnosed with a bacterial STI between July 1, 2023, and December 31, 2024, in whom factors associated with DoxyPEP receipt were evaluated using mixed-effects logistic regression. Among 219 patients prescribed DoxyPEP, 41% had a bacterial STI in the preceding year, more frequently among people with HIV (PWH) than PrEP users (51% vs. 30%,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.